Achieving LDL-particle targets deemed cost-effective

January 11, 2017

(HealthDay)—Achieving targets of low-density lipoprotein (LDL), as measured by LDL particle number (LDL-P) compared with LDL-cholesterol (LDL-C), is cost-effective, according to a study published in the Feb. 1 issue of The American Journal of Cardiology.

Michael Grabner, Ph.D., from HealthCore Inc. in Wilmington, Del., and examined the cost-effectiveness of LDL-lowering therapy guided by LDL-P among patients selected from the HealthCore Integrated Research Database who were followed for 12 to 36 months. The LDL-P cohort included patients who achieved LDL-P <1,000 nmol/L, while those without LDL-P tests but who achieved LDL-C <100 mg/dL were included in the LDL-C cohort. At the 12-, 24-, and 36-month follow-up, each cohort included 2,094, 1,242, and 705 patients, respectively.

The researchers found that, compared with in the LDL-C cohort, those in the LDL-P cohort received more aggressive lipid-lowering therapy and had fewer cardiovascular disease (CVD) events during follow-up. Over time, this correlated with increased pharmacy costs and lower medical costs. The incremental cost-effectiveness ratio estimates varied from $23,131, $3,439, and −$4,555 per CVD event avoided at 12, 24, and 36 months, respectively.

"LDL-lowering therapy guided by LDL-P was demonstrated to be cost-effective, with greater clinical and economic benefit seen over longer time horizons and with the increased use of generic statins," the authors write.

Several authors are employees of HealthCore, which received funding from LipoScience for the conduct of the study; two authors are employees of LipoScience.

Explore further: Fish oil supplementation tied to lower atherothrombotic risk

More information: Full Text

Related Stories

Fish oil supplementation tied to lower atherothrombotic risk

April 16, 2015

(HealthDay)—Fish oil supplementation (FOS) is associated with atherothrombotic risk reduction in suspected coronary artery disease (sCAD), according to a study published in the May 1 issue of The American Journal of Cardiology.

High-intensity statin effect independent of lipoprotein, CRP

November 13, 2014

(HealthDay)—High-intensity statin therapy is associated with coronary atherosclerosis regression, regardless of baseline lipoprotein or C-reactive protein (CRP) levels, according to a study published in the Nov. 15 issue ...

Many not treated according to 2013 cholesterol guidelines

November 25, 2014

(HealthDay)—Many patients are not being treated in accordance with the 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol guidelines, according to a study published in the Dec. 2 issue ...

Large variation in lipid reduction with high-dose statin tx

July 31, 2014

(HealthDay)—There is considerable interindividual variation in the magnitude of low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), and apolipoprotein B (apoB) reductions achieved ...

Glucose variation impacts coronary plaque vulnerability

May 19, 2015

(HealthDay)—For patients with coronary artery disease (CAD) pretreated with lipid-lowering therapy, daily glucose fluctuation may affect coronary plaque vulnerability, according to a study published in the May issue of ...

Recommended for you

Nigeria: Clean-burning stoves improve health for new mothers

January 13, 2017

In a small clinical trial that replaced widely used biomass and kerosene cookstoves with clean-burning ethanol stoves, a team of researchers from the University of Chicago and the University of Ibadan (Nigeria) was able to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.